We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Study: Speedy FDA Approvals Could Jeopardize Safety

Study: Speedy FDA Approvals Could Jeopardize Safety

August 7, 2014

Drugs launched after Congress passed legislation to accelerate the approval process are more likely to be given safety warnings or pulled from the market altogether, according to a new study critical of the FDA’s current review process.

Patient advocate group Public Citizen argues that the FDA doesn’t take the necessary time to study adverse outcomes before allowing products to go to market. That in turn raises the likelihood that drugs will be found to be dangerous after the fact, thus endangering patients, the group said.

Products cleared before the 1992 Prescription Drug User Fee Act, which sped approvals, had a 21.2 percent chance of eventually being given either a black box warning or being pulled for safety reasons, the study found. Drugs approved after PDUFA had a 26.7 percent chance of receiving the same outcomes, said the study that examined all non-biologic products approved from 1975 through 2009.

Public Citizen cautioned that it could not establish a direct causal link between the accelerated drug approvals and the likelihood of a safety finding.

Even so, study author and Public Citizen senior adviser Sidney Wolfe alleges that the FDA has been reckless in its approval speeds. On a conference call with reporters he dismissed the possibility that more warnings and safety withdrawals were issued because the agency has been quicker to respond to bad outcomes or the industry has been more responsive.

Wolfe and fellow study author Karen Lasser, an associate professor of medicine at Boston University School of Medicine, argued that healthcare providers should avoid prescribing any drug less than seven years old unless it is a breakthrough medication. The seven-year delay is necessary, they contend, because it gives adverse drug events enough time to be found and responded to.

An FDA spokesman said it was premature to comment on the study, but that the agency will review the study once it has been issued. — Bryan Koenig

Originally appeared in Drug Industry Daily, the pharmaceutical industry’s number one source for regulatory news and information. Click here for more information.

Pharmaceuticals Postmarket Safety

Upcoming Events

  • 21Jan

    Virtual MDSAP Audits in the Era of COVID-19: What to Know and Do to Pass Virtual Audits

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 27Jan

    FDA’s Response to COVID-19: Fundamentals of Obtaining Emergency Use Authorizations

  • 09Feb

    Maintaining Your Risk-Based Cleaning and Disinfectant Programs: Best Practices During COVID-19

  • 10Feb

    FDA Under the Biden Administration: What’s to Come and What It Will Mean

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • Regeneron logo

    U.S. Government Orders More Supplies of Regeneron’s COVID-19 Antibody Cocktail

  • Siemens Healthineers logo

    Siemens Healthineers COVID Test Gets Additional Sampling Method Clearance

  • COVID-19  Clinical Trial

    Synairgen Initiates Dosing in Late-Stage Trial of Inhaled COVID-19 Therapy

  • Verona Pharma logo

    Verona Pharma Ends Enrollment in Inhaler-Administered COVID-19 Drug Pilot

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing